trending Market Intelligence /marketintelligence/en/news-insights/trending/ft1ns3vu7miiv9vrlxy0ea2 content esgSubNav
In This List

Adaptimmune chief technology officer to resign

Blog

Insight Weekly: Private equity slows; SPAC underwriters retreat; carbon capture boost

Blog

Insight Weekly: M&A outlook; US community bank margins; green hydrogen players' EU expansion

Blog

Global M&A by the Numbers: Q2 2022

Blog

Insight Weekly: US bank M&A; low refinancing eases rates impact; Texas crypto mining booms


Adaptimmune chief technology officer to resign

Adaptimmune Therapeutics plc said Gwen Binder would step down as the company's chief technology officer at the end of January 2019.

Binder was the first U.S. employee of Adaptimmune in 2011, coming from the company's T-cell translational development collaboration program with the University of Pennsylvania.

Abingdon, U.K.-based Adaptimmune operates as a clinical-stage biopharmaceutical company that offers novel cancer immunotherapy products.